What NICE Says About Mounjaro — and What It Means in Practice

You've heard NICE approved Mounjaro, so why can't your GP prescribe it yet?

Picture this: you read that NICE gave Mounjaro the green light and you book an appointment with your GP, only to be told it isn't available yet. That's a frustrating but common experience, and it has a specific explanation.

NICE's TA1026 recommendation is phased. NHS England has set out a step-by-step rollout based on how many qualifying conditions a patient has alongside their BMI. The first cohort (adults with a BMI of 40 or above plus four or more of the five specified conditions (type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)) became eligible from June 2025. A second cohort covering BMI 35–39.9 with four or more of those conditions opened in late June 2026. Further cohorts follow through to around March 2027.

From April 2026, GP practices may prescribe Mounjaro under the new GP contract, but participation is optional; availability varies considerably by practice and by integrated care board area. Every NHS patient also needs to engage with wrap-around dietary and activity support as part of the programme. Meeting the criteria on paper does not guarantee a prescription will follow immediately. The NICE guidance on Mounjaro sets the clinical framework, but commissioning, funding, and capacity shape what actually happens at practice level.

What the TA1026 eligibility criteria actually say

NICE's TA1026 recommends tirzepatide for adults in England with a BMI of 35 kg/m² or above who also have at least one weight-related comorbidity. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the equivalent thresholds are 2.5 kg/m² lower throughout, so a qualifying BMI starts at 32.5 rather than 35.

The guidance also includes a review point: if a patient loses less than 5% of their body weight after six months at the highest dose they can tolerate, continuing treatment should be reconsidered. This is a clinical safeguard, not a punishment, it exists to ensure the medicine is working for that individual. If you want a closer look at how these criteria are applied in clinical practice, the Mounjaro NICE CKS resource is a useful reference for understanding how primary care teams interpret the guidance day to day.

One point worth flagging: the NICE criteria for NHS prescribing are stricter than the licensed criteria for private prescribing. The Mounjaro licence (the SmPC) permits use in adults with a BMI of 30 or above, or 27 and above where a weight-related condition is present. A private prescriber assessing someone through, say, a regulated private service works from the licensed criteria alongside a full clinical picture, not from TA1026 alone. That distinction explains how people who don't meet the NHS threshold can still be clinically suitable for a private prescription.

NICE on results: what the evidence showed

NICE's committee reviewed tirzepatide's evidence base in detail before issuing TA1026, and you can read more about that process on our NICE tirzepatide overview page, which covers how the appraisal unfolded and what the committee concluded. The pivotal data came from the SURMOUNT-1 trial, published in the New England Journal of Medicine, which randomised 2,539 adults with obesity over 72 weeks. At the 15mg maintenance dose, participants lost an average of around 20–21% of their body weight. The committee also noted that indirect comparisons across the evidence base favoured tirzepatide over semaglutide 2.4mg, a conclusion later supported by the direct head-to-head SURMOUNT-5 trial published in 2025.

These figures matter to the NICE process because the committee has to weigh clinical effectiveness against cost-effectiveness before recommending a medicine on the NHS. Tirzepatide's results were strong enough to cross that bar, even at the list prices that applied at the time of appraisal. For context on how UK pricing has moved since the recommendation, Eli Lilly raised Mounjaro's UK list price significantly from September 2025, a separate consideration from the NICE approval itself.

If you don't meet the NHS criteria, or can't wait, what NICE's approval changes for you

The NICE recommendation matters even to people accessing Mounjaro privately, because it validates the medicine's clinical credibility with the UK's most rigorous health technology body. Before TA1026, tirzepatide was licensed but appraised only provisionally; the full positive recommendation strengthened the evidence base that private prescribers draw on. If you are wondering whether access through a private route is possible from where you are, our guide to which countries Mounjaro is currently available in explains how availability and licensing differ across markets.

If your GP hasn't yet been commissioned to prescribe it, or your BMI or comorbidity profile sits outside the current NHS cohort, a private route through a regulated weight-loss service lets you access the same licensed medicine from the same UK supply chain, subject to your own clinical assessment. At nume, every consultation is read by a GPhC-registered Independent Prescriber (a named clinician, not an automated system) and if you're approved, your treatment is dispatched the same day for next-working-day delivery. The pen arrives in plain packaging via DPD, with tracking to your phone.

NICE's appraisal doesn't change the prescription requirement: Mounjaro remains a prescription-only medicine regardless of which route you use. What TA1026 provides is a thorough, independent confirmation that for the right patient it works, and works well. Whether the NHS or a private service is the right route for you is worth exploring with a prescriber. Check your eligibility with our clinical team to find out where you stand.